title: Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization.
abstract: In the United States, one-third of infected individuals contracted Human Immunodeficiency Virus-1 (HIV-1) via injecting drugs with contaminated needles or through risky behaviors associated with drug use. Research demonstrates concomitant administration of psychostimulants and HIV-1-proteins damage neurons to a greater extent than viral proteins or the drug alone. To model the onset of HIV-1-infection in relation to a history of drug use, the current research compared behavior and extracellular dopamine and metabolite levels following Tat(1-86) infusions in animals with and without a history of cocaine (Coc) experience (10 mg/kg; i.p.; 1 injection/day × 9 days). Animals receiving a behaviorally sensitizing regimen of Coc demonstrated a decrease in extracellular dopamine concentration in the nucleus accumbens, consistent with evidence describing up-regulation of dopamine transporter uptake. Contrary to this effect, Tat(1-86) microinfusion into the nucleus accumbens following the sensitizing regimen of Coc caused a significant increase in extracellular dopamine levels (nM) within 48 h with no difference in percent of baseline response to Coc. After 72 h, Tat + Coc treated animals demonstrated a blunted effect on potassium-stimulated extracellular dopamine release (percent of baseline) with a corresponding decrease in expression of behavioral sensitization to Coc challenge. A persistent decrease in extracellular dopamine metabolite levels was found across all time-points in Tat-treated animals, regardless of experience with Coc. The current study provides evidence for divergent neurochemical and behavioral outcomes following Tat-treatment; contingent upon experience with Coc.
authors.affiliation: Program in Behavioral Neuroscience, University of South Carolina, Columbia, South Carolina, USA. mferris@wfubmc.edu
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Ferris
authors.forename: Danielle
authors.initials: D
authors.lastname: Frederick-Duus
authors.forename: Jim
authors.initials: J
authors.lastname: Fadel
authors.forename: Charles F
authors.initials: CF
authors.lastname: Mactutus
authors.forename: Rosemarie M
authors.initials: RM
authors.lastname: Booze
mesh_terms: D000818:Animals; D003042:Cocaine / Q000494:pharmacology*; D019970:Cocaine-Related Disorders / Q000378:metabolism; D004298:Dopamine / Q000096:biosynthesis / Q000502:physiology*; D015497:HIV-1 / Q000187:drug effects; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000502:physiology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000502:physiology*
chemical_list: D054322:tat Gene Products, Human Immunodeficiency Virus; D003042:Cocaine; D004298:Dopamine
references.citation: J Neurosci Res. 1991 Mar;28(3):406-9
references.pmid: 1856886
references.citation: Acta Neuropathol. 2004 Mar;107(3):216-26
references.pmid: 14712399
references.citation: Neuroscience. 2006 Feb;137(3):925-35
references.pmid: 16338084
references.citation: Synapse. 2009 Mar;63(3):181-5
references.pmid: 19086089
references.citation: Neurotoxicology. 2008 Nov;29(6):971-7
references.pmid: 18606182
references.citation: Neurotox Res. 2005 Oct;8(1-2):51-61
references.pmid: 16260385
references.citation: J Neurovirol. 2006 Apr;12(2):140-5
references.pmid: 16798675
references.citation: J Neurosci. 2008 Sep 10;28(37):9092-100
references.pmid: 18784289
references.citation: J Pharmacol Exp Ther. 2009 Jun;329(3):1071-83
references.pmid: 19325033
references.citation: J Neurol Sci. 1994 Dec 1;127(1):114-20
references.pmid: 7699386
references.citation: Synapse. 2006 Jan;59(1):51-60
references.pmid: 16237680
references.citation: Am J Psychiatry. 1991 Nov;148(11):1558-61
references.pmid: 1681751
references.citation: Eur J Pharmacol. 1987 Jan 6;133(1):103-10
references.pmid: 3104064
references.citation: J Pharmacol Exp Ther. 2003 Apr;305(1):180-90
references.pmid: 12649367
references.citation: Neurosci Biobehav Rev. 2002 May;26(3):353-9
references.pmid: 12034135
references.citation: Neuropsychopharmacology. 2005 Aug;30(8):1455-63
references.pmid: 15702135
references.citation: Neurology. 1993 Oct;43(10):2099-104
references.pmid: 8413973
references.citation: Am J Epidemiol. 2002 Jan 15;155(2):159-68
references.pmid: 11790680
references.citation: Psychopharmacology (Berl). 1980;72(1):27-33
references.pmid: 6781004
references.citation: Brain Res. 2000 Oct 6;879(1-2):42-9
references.pmid: 11011004
references.citation: Synapse. 1989;3(1):48-54
references.pmid: 2537539
references.citation: Nat Neurosci. 2006 Aug;9(8):1050-6
references.pmid: 16829955
references.citation: Neuroscience. 2009 Apr 10;159(4):1292-9
references.pmid: 19344635
references.citation: J Neurochem. 2008 Nov;107(4):928-40
references.pmid: 18786172
references.citation: Eur J Pharmacol. 1986 Dec 2;132(1):1-9
references.pmid: 3816961
references.citation: J Acquir Immune Defic Syndr (1988). 1992;5(11):1116-8
references.pmid: 1403641
references.citation: Pharmacol Biochem Behav. 2005 Sep;82(1):170-81
references.pmid: 16139878
references.citation: J Pineal Res. 2004 Apr;36(3):177-85
references.pmid: 15009508
references.citation: Eur J Neurosci. 2009 Nov;30(10):1931-40
references.pmid: 19912338
references.citation: Synapse. 1990;5(1):48-58
references.pmid: 2300906
references.citation: Psychopharmacology (Berl). 2008 Jan;195(4):517-25
references.pmid: 17879088
references.citation: Semin Cell Dev Biol. 2009 Jun;20(4):411-7
references.pmid: 19560046
references.citation: J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):248-54
references.pmid: 11449032
references.citation: AIDS. 2006 Apr 4;20(6):805-12
references.pmid: 16549963
references.citation: Neuroimage. 2008 Aug 15;42(2):869-78
references.pmid: 18579413
references.citation: AAPS J. 2006 May 12;8(2):E337-47
references.pmid: 16796384
references.citation: J Neurol. 2009 Jun;256(6):948-53
references.pmid: 19240951
references.citation: Drug Alcohol Depend. 2005 Jul;79(1):63-70
references.pmid: 15943945
references.citation: Neurosci Biobehav Rev. 2008 Jul;32(5):883-909
references.pmid: 18430470
references.citation: J Neuroimmune Pharmacol. 2008 Dec;3(4):203-17
references.pmid: 18709468
references.citation: Acta Neuropathol. 2001 Feb;101(2):85-91
references.pmid: 11271377
references.citation: Ann N Y Acad Sci. 2010 Feb;1187:122-8
references.pmid: 20201849
references.citation: Brain Res. 2003 Sep 12;984(1-2):133-42
references.pmid: 12932847
references.citation: J Neurochem. 2008 Aug;106(4):1731-44
references.pmid: 18624911
references.citation: Clin Neuropharmacol. 2000 Jul-Aug;23(4):190-4
references.pmid: 11020122
references.citation: Neurosci Lett. 2006 Mar 13;395(3):235-9
references.pmid: 16356633
references.citation: Pharmacol Biochem Behav. 2008 Oct;90(4):723-9
references.pmid: 18582493
references.citation: Drug Alcohol Depend. 2008 Nov 1;98(1-2):70-6
references.pmid: 18565692